Home | Publications | Production / Manufacturing place holder
place holder place holder

Production / Manufacturing

Partnering And Business Trends In Transgenic Manufacturing


Publication Date   January 2004
Publisher   CredoLegal
Product Type   Brief
Pages   15
ISBN Number   not applicable
Product Code   CRE005
Ask a question about this product?

Price £95.00

approximately: $188 | €121

Summary


In early days of biotechnology, excess manufacturing capacity put many contract manufacturing organizations (CMOs) in a weak position. Many CMOs for example Verax Corp, Damon Biotech, Bioresponse Inc, failed in part because producers like Johnson and Johnson built their own facilities. However, in recent years many CMOs have generated positive returns. Recognition of the downside risk of capacity shortages has prompted many companies to sign up for capacity.

The worldwide market for protein manufacturing represents a substantial and growing portion of the value chain for pharmaceutical companies and presents an attractive opportunity for transgenic based manufacturers to expand their businesses. Although transgenic production represents a small portion of the current market, the impending shortage in traditional manufacturing capacity will likely compel pharmaceutical companies to reassess their long-term production strategies and provide a substantial near-term opportunity for transgenic-based companies to gain market penetration. Most contract manufacturers are currently sold out or are approaching full capacity for their mammalian cell culture facilities. However, planned cell culture expansions are significant in scale as CMOs are upgrading their current capacity. In addition to the rapidly growing contract manufacturing market, in-house manufacturing is expected to continue to grow rapidly and contribute to a total protein manufacturing market of over $6.4 billion by 2005

Several companies have entered into human clinical trials with transgenic proteins, as presented in the Table below.

Content


Chapter 1. Business trends and market opportunity analysis in biologics manufacturing


Chapter 2. Market segments and market size for biologics therapeutics in the USA


Chapter 3. Partnerships and clinical development stage of transgenic manufactured therapeutics


Chapter 4. Strategic Objectives for alliances

Strategy assumptions
Key strategies
New products/therapies
Core analysis


List Of Tables


Table I. Selected manufacturing platforms


Table II. Worldwide Protein Manufacturing Market


Table III: Examples of transgenic therapeutics in clinical trials, and their development stage


Table IV. Alliance options available for TMs



List of Figures


Figure I . Alliance networks available for TM in the antibody arena